Michael D Mühlebach
Nürnberger C, Bodmer B, Fiedler A, Gabriel G, Mühlebach M. A measles virus-based vaccine candidate mediates protection against Zika virus in an allogenic mouse pregnancy model. J Virol. 2018;: pubmed publisher
Gogesch P, Schülke S, Scheurer S, Mühlebach M, Waibler Z. Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b+ APC and antigen-specific T cell responses in vitro. Mol Immunol. 2018;101:19-28 pubmed publisher
..These data suggest MLV-VLPs to be an attractive platform to flexibly combine antigen and adjuvant for novel modular vaccination approaches. ..
Bodmer B, Fiedler A, Hanauer J, Prüfer S, Mühlebach M. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. Virology. 2018;521:99-107 pubmed publisher
Uhlig K, SchÃ¼lke S, Scheuplein V, Malczyk A, Reusch J, Kugelmann S, et al
. Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response. J Virol. 2015;89:9044-60 pubmed publisher
..Thereby, the potential for easy envelope exchange allows the circumventing of neutralizing antibodies, e.g., during repeated boost immunizations. ..
Malczyk A, Kupke A, PrÃ¼fer S, Scheuplein V, Hutzler S, Kreuz D, et al
. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. J Virol. 2015;89:11654-67 pubmed publisher
..Subsequent challenge experiments indicated protection of vaccinated animals, illustrating the potential of MV as a vaccine platform with the potential to target emerging infections, such as MERS-CoV. ..
Hutzler S, Erbar S, Jabulowsky R, Hanauer J, Schnotz J, Beissert T, et al
. Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles. Sci Rep. 2017;7:16892 pubmed publisher
..These data indicate the potential of MV to trigger selected tumor antigen-specific immune responses on top of direct tumor lysis for enhanced efficacy. ..
Mühlebach M, Hutzler S. Development of Recombinant Measles Virus-Based Vaccines. Methods Mol Biol. 2017;1581:151-168 pubmed publisher
Mühlebach M. Vaccine platform recombinant measles virus. Virus Genes. 2017;53:733-740 pubmed publisher
..Thereby, recombinant measles vaccines expressing additional antigens are a promising platform for future vaccines. ..